Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

May 15, 2022

Study Completion Date

February 5, 2025

Conditions

High Tumor Mutation BurdenHigh TMB (Tumor Mutation Burden)MSS (Microsatellite Stable)

Interventions

DRUG

MK-3475

MK-3475 (pembrolizumab) 200 mg flat dose every 21 days

Trial Locations (3)

Memorial Sloan Kettering Cancer Center, New York

Sidney Kimmel Comprehensive Cancer Center, Baltimore

Ohio State University, Columbus

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT04098068 - Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) | Biotech Hunter | Biotech Hunter